The soluble suppression of tumorigenicity-2 protein
ST2 (growth-stimulating expression gene 2 protein) is a member of the interleukin-1 (IL-1) receptor family, including transmembrane (ST2L) and soluble (sST2). sST2 is mainly expressed on the surface of mast cells and helper T cell-like lymphocytes, and can be secreted outside the cell. Studies have found that the ligand of ST2L is interleukin-33 (IL-33). Animal model experiments have verified that the IL33/ST2L signaling pathway can control cardiomyocyte hypertrophy and cardiac fibrosis to play a cardioprotective effect, while sST2 acts as a decoy receptor and IL33 binds to block the IL33/ST2L signaling pathway . A large amount of sST2 is generated in the process of myocardial damage caused by excessive stretching, and combines with IL-33, thereby blocking the complete IL-33/ST2L signaling pathway to play a protective role, leading to accelerated myocardial remodeling and ventricular dysfunction .
Therefore, sST2 can be detected in the blood when heart failure occurs or when chronic heart failure worsens, or when the myocardium cannot stretch well due to scars caused by myocardial infarction. sST2 is an independent index predicting the short-term mortality of patients with acute decompensated heart failure, chronic heart failure, and myocardial infarction . sST2 is not affected by age, renal impairment and body mass index , and its diagnostic performance for heart failure in hypertensive populations with normal ejection fraction is better than NT-proBNP .
Numerous clinical studies have shown that sST2 is a new cardiac marker, and its elevated level is closely related to the risk stratification and prognosis of acute and chronic heart failure (heart failure). The "2018 Chinese Guidelines for the Diagnosis and Treatment of Heart Failure" pointed out that the detection of sST2 is helpful for the risk stratification and prognosis assessment of patients with heart failure . The updated ACC\AHA\HFSA guidelines in 2017 proposed that sST2 is a marker of acute heart failure and hospitalization that reflects myocardial injury or myocardial fibrosis .
When the sample concentration is 25.0ng/mL, the absorbance change should ≥ 0.0100.
In the range of [5.0, 400.0]ng/mL, the linearity correlation coefficient r ≥ 0.990. In the range of [5.0, 100.00]ng/mL, the absolute deviation should ≤ 10.0ng/mL; In the range of (100.0, 400.0] ng/mL, the relative deviation should ≤10%.
Using the pure soluble growth-stimulating expression gene 2 protein antigen antigen to do the recovery experiment, the recovery rate is 85%-115%.
When the following substances were dissolved into serum samples with a base concentration of 50±5.0 ng/mL for determination, the effect of bilirubin ≤ 50 mg/dL, hemoglobin ≤500mg/dL, RF ≤ 400IU/mL, Fat emulsion ≤ 1%, is less than 10%.